Business
Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting
Company to Host Scientific Exhibit on Monday, December 9 from 8:00 am ET to 11:00 am ET Company to Host Investor & Analyst Libervant Update Forum and Webcast
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"Company to Host Scientific Exhibit on Monday, December 9 from 8:00 am ET to 11:00 am ET\n Company to Host Investor & Analyst Libervant Update Forum and Webcast on Monday, December 9 at 4:00 pm ET WARREN, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that data from five abstracts, including two “late-breakers”, related to its therapeutic candidate, Libervant™ (diazepam) Buccal Film, will be presented at the American Epilepsy Society (AES) 2019 Annual Meeting, taking place December 6-10, 2019 in Baltimore. In addition to the poster presentations, Aquestive will host a Scientific Exhibit on Monday, December 9th from 8:00 am – 11:00 am ET at the Baltimore Convention Center in Rooms 318-319, Level 300. Study investigators and authors will be present to discuss the posters in more detail and answer questions. Below is an overview of the poster presentations: Title: Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epilepsy: Comparison with Diazepam Rectal Gel Poster Number: 1.432Presenter: Michael A. Rogawski, MD, PhD, Professor of Neurology and Pharmacology, School of Medicine, University of California, DavisDate/Time: Saturday, December 7, 12 pm – 2 pm ETLocation: Hall E, Level 100 Title: Patient and Caregiver Preference for Route of Administration of a Benzodiazepine for Control of Increased Seizure Activity in Stable Patients Poster Number: 2.129 Presenter: Ahmed Abdel-Razek, MD, Head of Medical Affairs, Aquestive TherapeuticsDate/Time: Sunday, December 8, 12 pm – 2 pm ETLocation: Hall E, Level 100 Title: Unreliable Absorption with Rectal Administration of DiazepamPoster Number: 2.258Presenter: Gary Slatko, MD, Chief Medical Officer, Aquestive TherapeuticsDate/Time: Sunday, December 8, 12 pm – 2 pm ETLocation: Hall E, Level 100 Title: Simulation of the Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epilepsy with Weight-adjusted Dosing Poster number: 3.304Presenter: Allen H. Heller, MD, MPH, Pharma Study Design LLCDate/Time: Monday, December 9, 12 pm – 1:45 pm ETLocation: Hall E, Level 100 Title: Safety and Tolerability Associated with Chronic Intermittent Use of Diazepam Buccal Film in...